- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, ... Read More Close
KYPROLIS® demonstrated up to 42 months of mPFS when paired with an anti-CD38 mAb + dex1,2
DKd
KYPROLIS® + daratumumab + dexamethasone
CANDOR trial (DKd vs Kd):1,* Randomized, open-label, multicenter trial of 466 patients who were randomized 2:1 to receive DKd (n = 312) or Kd (n = 154) with KYPROLIS® 56 mg/m2 twice weekly. At a median follow-up of nearly 28 months, mPFS was 28.6 months for DKd vs 15.2 months for Kd (HR = 0.59; 95% CI: 0.45-0.78).
Isa-Kd
KYPROLIS® + isatuximab-irfc + dexamethasone
IKEMA trial (Isa-Kd vs Kd):2,3,†,‡ Randomized, open-label, multicenter trial of 302 patients who were randomized 3:2 to receive Isa-Kd (n = 179) or Kd (n = 123) with KYPROLIS® 56 mg/m2 twice weekly. At a median follow-up of 44 months, mPFS was 41.7 months for Isa-Kd vs 20.8 months for Kd (HR = 0.59; 95.4% CI: 0.42-0.83).
*As of the primary analysis, with a median follow-up of ~ 17 months, the primary endpoint of improved median PFS was met. Median PFS was not reached for DKd vs 15.8 months for Kd (HR = 0.63; 95% CI: 0.46-0.85; P = 0.0014, one-sided).1,4
†As of the primary analysis, with a median follow-up of 20.7 months, the primary endpoint of improved median PFS was met. Median PFS was not reached for Isa-Kd vs 20.27 months for Kd (HR = 0.55; 95% CI: 0.37-0.82; P = 0.0032).3
‡Analysis censoring PFS events occurring > 8 weeks from the last valid disease assessment.2
CI, confidence interval; dex, dexamethasone; HR, hazard ratio; Kd, carfilzomib + dexamethasone; mAb, monoclonal antibody; mPFS, median progression-free survival; PFS, progression-free survival.
For patients at first relapse, KYPROLIS® + an anti-CD38 mAb + dex* may power their possibilities
A treatment history that is common for many RRMM patients approaching their first relapse
A 68-year-old patient with standard cytogenetic risk,† was diagnosed with multiple myeloma in 2019. She has been on lenalidomide maintenance therapy, and recent lab results suggest she may be entering relapse.‡
*Carfilzomib + isatuximab-irfc + dexamethasone; carfilzomib + daratumumab + dexamethasone.
†Standard-risk is defined as having any cytogenetics other than the abnormalities t(4;14), t(14;16), or del(17p).5
‡Hypothetical patient profile.
ASCT, autologous stem cell transplant; mAb, monoclonal antibody; RRMM, relapsed or refractory multiple myeloma; VRd, bortezomib + lenalidomide + dexamethasone.
Please see accompanying full Prescribing Information.
Please see accompanying full Prescribing Information.
References: 1. Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23:65-76. 2. Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023;13:72. 3. SARCLISA® (isatuximab-irfc) prescribing information. Bridgewater, NJ: sanofi-aventis U.S. 4. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 5. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186-197.